Staphylococcus aureus, MRSA & MSSA Infection Models

Staphylococcus aureus (S. aureus) is a Gram-positive coccus that colonizes the nose and skin of a large fraction of healthy people and turns pathogenic when it breaches the skin or mucosa. It causes the widest disease range of the ESKAPE group – from the skin and soft tissue infections that make up most of its clinical burden, through wound, device, and prosthetic infections, to invasive bacteremia, endocarditis, osteomyelitis, and pneumonia. Its difficulty in treatment comes from its toolkit of toxins, adhesins, and biofilm that lets it establish and persist on tissue and hardware, and its acquired resistance that limits the number of drugs that are able to effectively treat it. 

The pivotal distinction is methicillin resistance, which is why methicillin-resistant S. aureus (MRSA) is designated a serious threat by the CDC and a high-priority pathogen on the WHO Bacterial Priority Pathogens List. TransPharm Preclinical Solutions evaluates candidates against both MRSA and MSSA in vivo across seven validated infection models, from topical skin challenges to bone and bloodstream disease, and produces the quantitative burden and survival data a development program needs.

S. aureus is a catalase- and coagulase-positive coccus that grows in grape-like clusters and readily forms biofilm on catheters, prosthetic joints, and devitalized tissue. It is a commensal on roughly a third of the population, which is also the reservoir for most infections: the same isolate that colonizes the nose can seed a surgical wound or a bloodstream once the barrier is broken. That combination of ubiquity, tissue range, and resistance is what makes it a central target for new antibacterials.

The scientific problem in an S. aureus study is matching the challenge to the question. Because skin and soft tissue infections dominate the clinical burden while the organism’s most lethal disease is invasive, the model and the infection site have to be chosen deliberately – a topical skin challenge, a deep wound, a bone infection, and a bloodstream infection each answer a different development question. 

Strain choice is equally load-bearing: a methicillin-susceptible reference strain, a community-associated MRSA isolate such as USA300, and a vancomycin-intermediate strain will each interrogate a candidate differently. Biofilm on devices, in bone, and in abscesses can dissociate in vitro susceptibility from in vivo effect, so the site and the readout determine whether a study is interpretable. 

TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens, including many multidrug-resistant strains, from which challenge strains can be selected or validated to a program’s needs.

Every study parameter – challenge strain, host species and strain, route of administration, comparator agents, and dosing schedule –  is configurable to the scientific question. The core readouts are quantitative bacterial burden (CFU/g or CFU/mL) in target tissues, organs, and blood, with survival and mortality tracking where applicable.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

Bacteremia – bacteria in normally sterile blood – is among the most serious S. aureus presentations, prone to metastatic seeding of the heart, bone, and deep tissue, and carrying high mortality rates. The model screens systemic activity and ranks candidates on survival and on bacterial burden in blood and organs. Animals are challenged by intravenous injection in the lateral tail vein. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include survival (mortality tracking) and CFU burden in blood and harvested organs. Validated in mice, with rats available on request. Validated S. aureus isolates: ATCC 25904 (Newman D2C) and USA300 (MRSA).

Skin and soft tissue infections make up the largest share of S. aureus disease. In the deep-wound model, a 6 mm biopsy punch creates a full-thickness wound over the thoracic spine on the dorsal surface, and bacterial broth is inoculated directly into the wound. Test article may be administered topically or by oral gavage or subcutaneous, intraperitoneal, or intravenous injection. The primary endpoint is quantitative bacterial burden (CFU) in the harvested wound skin. Validated in mice, with rats available on request. Validated S. aureus isolate: USA300 (MRSA).

The tape-stripping model reproduces superficial skin infection: surgical tape is repeatedly applied to and removed from a shaved area on the back to disrupt the epidermal barrier, after which the site is challenged with a topical inoculation. It is the appropriate model for topical agents and for early skin and soft tissue indications where the target is the epidermal surface rather than deep tissue. The primary endpoint is quantitative bacterial burden (CFU) in the harvested skin. Validated in mice. Validated S. aureus isolate: USA300 (MRSA).

Osteomyelitis, or infection of the bone, is a signature S. aureus complication and a complex therapeutic problem, because the organism persists in bone, within biofilm, and inside host cells beyond the reach of many agents.

TransPharm Preclinical Solutions’s model is a non-surgical, chronic osteomyelitis established in rats: bacteria are delivered by intraosseous injection into the cancellous bone marrow through the anterior surface of the proximal tibia, and the infection is allowed to establish for up to four weeks. Test article is typically administered by oral gavage or by intravenous or intraperitoneal injection. The endpoint is CFU burden in the harvested tibia, with histopathology available to document bone involvement. This is the model to use when the development question is penetration and activity in established, chronic bone infection. Validated S. aureus isolates: ATCC 49230 (UAMS-1, a methicillin-susceptible clinical osteomyelitis isolate), ATCC BAA-1556 and ATCC BAA-1756 (USA300 community-associated MRSA), and clinical strain 3527.

Peritonitis, inflammation of the peritoneal lining, is a rapidly progressive systemic challenge well suited to ranking candidates on survival under a high bacterial load. Animals are challenged by intraperitoneal injection, often with gastric mucin to help establish infection. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include mortality tracking and CFU burden in harvested organs and/or blood. Validated in mice and rats. Validated S. aureus isolates: ATCC 13709, ATCC 33592, ATCC BAA-1707 (USA400 MRSA), UC-76-rp, USA300 (MRSA), and 01A1095.

S. aureus pneumonia – including necrotizing pneumonia and ventilator-associated disease – is a severe presentation that is reproduced by TransPharm Preclinical Solutions’s pulmonary model. Animals are challenged by intranasal or intratracheal instillation. Test article may be delivered by nebulization, oral gavage, intranasal or intratracheal instillation, or by intravenous, intraperitoneal, intramuscular, or subcutaneous injection. Endpoints include mortality tracking and CFU burden in lung and other harvested tissues. Validated in mice and rats. Validated S. aureus isolates: ATCC 33591 (MRSA), ATCC BAA-1556 (USA300 MRSA), and USA300 (MRSA).

The soft tissue model establishes a localized infection in the muscle by intramuscular injection into one or both quadriceps, giving a quantifiable burden well suited to PK/PD and dose-ranging work. Test article may be administered by oral gavage or by subcutaneous, intravenous, or intraperitoneal injection. Endpoints include CFU burden at the infected site and in harvested organs and/or blood, with mortality tracking. Validated in mice. Validated S. aureus isolates: ATCC BAA-1717 (USA300-HOU MRSA), ATCC 29213 (a methicillin-susceptible QC strain), and USA300 (MRSA).

The in vivo models are paired with in vitro susceptibility testing: MIC by agar and broth dilution per CLSI, along with MBC, time-kill kinetics, and checkerboard analysis. For S. aureus, time-kill and checkerboard data are often where a combination regimen or a resistance-breaker candidate is first differentiated.

Whether an isolate is methicillin-resistant (MRSA) or methicillin-susceptible (MSSA) is the single most important variable in an S. aureus study. Methicillin resistance is conferred by the mecA gene – or its mecC variant – carried on the mobile SCCmec cassette, which encodes PBP2a, a penicillin-binding protein with low affinity for β-lactams. An MRSA isolate is therefore resistant to nearly the entire β-lactam class – penicillins, cephalosporins, and carbapenems – apart from the newer anti-MRSA cephalosporins, while MSSA remains treatable with antistaphylococcal β-lactams even when it produces penicillinase. 

However, resistance does not stop there: vancomycin-intermediate (VISA) and heteroresistant (hVISA) strains raise vancomycin MICs by thickening the cell wall, rare vancomycin-resistant (VRSA) strains carry the enterococcal vanA operon, and reduced susceptibility to linezolid and daptomycin has been reported. Because “MRSA” spans this range rather than a single susceptibility phenotype, the resistance profile of the challenge strain determines what an efficacy study can claim.

TransPharm Preclinical Solutions’s validated roster reflects that range. It includes methicillin-susceptible strains – among them ATCC 49230 (UAMS-1), the classic bone-derived osteomyelitis isolate, along with ATCC 25904 (Newman) and the ATCC 29213 QC strain – and multiple community-associated MRSA lineages, including USA300 (ATCC BAA-1556, BAA-1717, and BAA-1756) and USA400 (ATCC BAA-1707). Characterized reference or clinical isolates, including additional defined resistant phenotypes, can be sourced or validated to a program’s specifications.